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of the ethnic categories. Only 15.6% and 9.7% of the patients
had lipid tests and LFTs within three months since the start 
of therapy. Non-Hispanic blacks were less likely to have lipid
tests compared to non-Hispanic whites (OR = 0.804; 95% CI,
0.653–0.990). Presence of coronary heart disease (OR = 1.305;
95% CI, 1.093–1.556) and lipid test prior to the start of therapy
(OR = 4.207; 95% CI, 3.607–4.908) were associated with an
increased likelihood of lipid tests after the start of therapy. Older
patients (OR = 0.987; 95% CI, 0.977–0.997) and non-Hispanic
blacks (OR = 0.543; 95% CI, 0.413–0.713) had a lower likeli-
hood of having LFTs than younger patients and whites. Presence
of hypertension (OR = 1.312; 95% CI, 1.081–1.592) and prior
LFTs (OR = 3.561; 95% CI, 2.939–4.315) were associated with
an increased likelihood of LFTs after the start of therapy. CON-
CLUSION: Monitoring of lipid levels and adverse events for
patients on statin therapy remains suboptimal. There exists an
ethnic disparity in the management of hyperlipidemia.
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OBJECTIVES: To examine effect of co-payment on the initia-
tion of statins after coronary heart disease (CHD) hospitali-
zation. METHODS: Medstat Marketscan commercial and
Medicare 1999–2002 databases including inpatient admission,
outpatient and pharmacy claims were utilized for this study. The
ﬁrst CHD hospital admission was identiﬁed as the index hospi-
talization. The study sample consisted of adults who had no
statin use during the year prior to the index hospitalization and
had at least six-month follow up after discharge. The outcome
was the initiation of any statin prescription during six-month
follow up. Effect of co-payment on the initiation of statins was
examined by a multiple logistic regression, controlling for age,
gender, region, year of the index hospitalization, length of 
stay, baseline comorbidity, baseline number of drug therapeutic
classes, and baseline non-statin lipid-lowering drug use.
RESULTS: A total of 12,182 subjects met the inclusion criteria
and were included in the analysis. Only 5411 (44.41%) had ini-
tiated statin therapy within six-months after discharge. Com-
pared with those who had a co-payment less than or equal to
$10, subjects with a co-payment over $20 were about two thirds
less likely to initiate statin therapy (OR, 0.34; 95% CI,
0.29–0.39), while subjects with a co-payment between $10 to
$20 were about 14% less likely. (OR: 0.86; 95% CI, 0.76–0.97).
Other signiﬁcant factors were baseline comorbidities including
congestive heart failure, hypertension, diabetes, hyperlipidemia;
baseline number of drug therapeutic classes, baseline non-statin
lipid-lowering drug use, age, and year of hospitalization. CON-
CLUSIONS: Fewer than half the patients received statin therapy
after CHD hospitalization. Co-payment appears to be a signiﬁ-
cant barrier to the initiation of statins, even after adjusting for
other demographic and clinical variables.
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Many studies have shown that high serum concentrations of
LDL-C are a major risk factor for coronary heart disease (CHD)
and that lowering LDL-C levels will reduce the risk of major
coronary events. Despite the availability of the National Cho-
lesterol Education Program Adult Treatment Panel III (ATP III)
guidelines for the management of hyperlipidemia, most patients
do not achieve their target LDL goals. OBJECTIVE: To evalu-
ate the impact of clinical pharmacist intervention on LDL-C 
outcomes, in patients at high risk of cardiovascular events.
METHODS: Forty-six patients with clinical atherosclerosis, a
disease that confers high risk for CHD events, under the age of
70 with LDL >110mg/dL were identiﬁed from the data systems
of Maccabi Healthcare Services (study group). The clinical phar-
macist intervention consisted of meeting the physicians in order
to present and discuss information regarding the ATP III recom-
mendations on the management of hyperlipidaemia, and to go
over patients clinical charts. Meetings were followed by written
recommendations regarding LDL management and by periodic
telephone follow-up to ensure implementation of the recom-
mendations. Outcome analysis was based on a comparison
between the study group and a control group (169 patients with
similar characteristics). RESULTS: After 6-months follow-up
81% of the patients in the study group showed an improvement
in LDL levels, with 24% achieving the ATP III goal for high risk
patients of LDL <100mg/dL. In the control group the numbers
were 61% and 16% respectively. CONCLUSION: Results of
several studies evaluating intervention programs indicate that
pharmacists can play a key role in improving cholesterol man-
agement in lipid clinics, community pharmacies, or hospitals.
This study demonstrates for the ﬁrst time in Israel that clinical
pharmacist can have a positive impact on meeting LDL-C goals
and better treatment outcomes.
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OBJECTIVES: This study investigated in French primary care,
the association between LDL-cholesterol goal attainment (LDL-
C < 130mg/dL in national guidelines) during three consecutive
years and occurrence of cardiovascular events (CV) in multiple
CV risk factor (three or more) patients, without coronary heart
disease history. METHODS: A total of 579 patients treated with
lipid lowering drugs (LLD) for three-years and with a yearly doc-
umented LDL-C (2000–2002) were consecutively included by
236 primary care physicians. Patients were classiﬁed into three
groups according to the number of consecutive years they
attained TO: all 3 years (TO+++: n = 145), only part of the time
(TO intermediate: n = 256), and never (TO---: n = 178). CV
risk factors and CV events (angina pectoris, myocardial infarc-
tion, heart failure, stroke, peripheral artery disease) occurring
during the last year of observation, 2002, were retrospectively
collected through computerized medical records (Thales data-
base) and a speciﬁc questionnaire. The risk of occurrence of a
CV events was studied according to TO status. Logistic regres-
sion model was used, to adjust for baseline differences in CV risk
factors. RESULTS: Only 25% of patients reached TO during all
three years. Patients with at least one CV event were 5.5%,
10.5% and 12.9% respectively in the TO+++, TO intermediate
and TO--- groups. Compared to TO+++, signiﬁcantly increased
risk of CV event was observed, both for TO intermediate (OR
